Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days, allowing for every other month parenteral administrations...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tian, Su, Hang, Dash, Prasanta, Lin, Zhiyi, Shetty, Bhagya Laxmi Dyavar, Kocher, Ted, Szlachetka, Adam, Lamberty, Benjamin, Fox, Howard S., Poluektova, Larisa, Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Mosley, R. Lee, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926202/
https://www.ncbi.nlm.nih.gov/pubmed/29059541
http://dx.doi.org/10.1016/j.biomaterials.2017.10.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926202/
https://www.ncbi.nlm.nih.gov/pubmed/29059541
http://dx.doi.org/10.1016/j.biomaterials.2017.10.023

Ejemplares similares